ATE432263T1 - Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer - Google Patents

Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer

Info

Publication number
ATE432263T1
ATE432263T1 AT00969903T AT00969903T ATE432263T1 AT E432263 T1 ATE432263 T1 AT E432263T1 AT 00969903 T AT00969903 T AT 00969903T AT 00969903 T AT00969903 T AT 00969903T AT E432263 T1 ATE432263 T1 AT E432263T1
Authority
AT
Austria
Prior art keywords
ylmethanol
steroid
imidazole
derivatives
tumors
Prior art date
Application number
AT00969903T
Other languages
English (en)
Inventor
Akihiro Tasaka
Akio Ojida
Tomohiro Kaku
Masami Kusaka
Masuo Yamaoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE432263T1 publication Critical patent/ATE432263T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00969903T 1999-10-22 2000-10-19 Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer ATE432263T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP30155699 1999-10-22
JP2000189728 2000-06-20
PCT/JP2000/007283 WO2001030762A1 (en) 1999-10-22 2000-10-19 Imidazol-4-ylmethanols use as inhibitors of steroid c17-20 lyase

Publications (1)

Publication Number Publication Date
ATE432263T1 true ATE432263T1 (de) 2009-06-15

Family

ID=26562739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00969903T ATE432263T1 (de) 1999-10-22 2000-10-19 Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer

Country Status (9)

Country Link
US (1) US6649643B1 (de)
EP (1) EP1222174B1 (de)
AT (1) ATE432263T1 (de)
AU (1) AU7950000A (de)
CA (1) CA2387869A1 (de)
CO (1) CO5251418A1 (de)
DE (1) DE60042274D1 (de)
PE (1) PE20010781A1 (de)
WO (1) WO2001030762A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020596A1 (es) * 2000-11-17 2002-08-13 Takeda Chemical Industries Ltd Derivados de imidazol, metodos de produccion e intermediarios del mismo
ATE502030T1 (de) * 2000-11-20 2011-04-15 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
MXPA06000401A (es) * 2003-07-10 2006-03-17 Osi Pharm Inc Derivados de naftileno como inhibidores de citocromo p450.
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
RU2008130448A (ru) 2006-01-27 2010-03-10 Ф. Хоффманн-Ля Рош Аг (Ch) Применение производных 4-имидазола для расстройств цнс
RU2009112496A (ru) 2006-10-19 2010-11-27 Ф. Хоффманн-Ля Рош Аг (Ch) Аминометил-4-имидазолы
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
JP2010510184A (ja) 2006-11-16 2010-04-02 エフ.ホフマン−ラ ロシュ アーゲー 置換4−イミダゾール類
CA2672617A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2-imidazoles as ligands for trace amine associated receptors (taar)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
CN101600700B (zh) 2007-02-02 2013-08-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体用于cns病症的新的2-氨基噁唑啉
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Taar1 리간드로서의 2-아미노옥사졸린
CN101687812A (zh) 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
CA2691704A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ.ホフマン−ラ ロシュ アーゲー Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
PE20090931A1 (es) * 2007-10-29 2009-08-03 Takeda Pharmaceutical Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
JP6082353B2 (ja) 2011-06-15 2017-02-15 武田薬品工業株式会社 イミダゾール誘導体の製造方法
CN108713019B (zh) 2016-03-17 2021-06-15 豪夫迈·罗氏有限公司 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物
CN105884691B (zh) * 2016-06-02 2017-08-25 江苏恒瑞医药股份有限公司 一种制备右美托咪定及其中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1238640A (en) * 1984-06-18 1988-06-28 Kenneth S. Hirsch 4(5)-substituted imidazoles
IS1756B (is) * 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
WO1995009157A1 (en) * 1993-09-30 1995-04-06 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
CA2213246A1 (en) * 1995-03-01 1996-09-06 Yamanouchi Pharmaceutical Co., Ltd. Imidazole derivatives and medicinal composition thereof
EP1073640B1 (de) 1998-04-23 2005-04-13 Takeda Pharmaceutical Company Limited Naphthalene derivate ,ihre herstellung und verwendung
WO2000078727A1 (en) * 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Process for the preparation of imidazole derivatives
WO2001030763A1 (en) 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. Process for producing optically active naphthalene derivative and optical resolver therefor

Also Published As

Publication number Publication date
EP1222174A1 (de) 2002-07-17
WO2001030762A1 (en) 2001-05-03
PE20010781A1 (es) 2001-08-08
DE60042274D1 (de) 2009-07-09
AU7950000A (en) 2001-05-08
EP1222174B1 (de) 2009-05-27
CO5251418A1 (es) 2003-02-28
US6649643B1 (en) 2003-11-18
CA2387869A1 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
ATE432263T1 (de) Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer
DE60309667D1 (de) Biphenylderivate und ihre verwendung als antiandrogene
DE69928697D1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE59904462D1 (de) Androgene in kombination mit gestagene zum ausgleich eines testosteron-defizits mit schutz der prostata
GB2389491A (en) Radio frequency transmitter and methods thereof
AU2002340010A1 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
AU3685601A (en) Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
MX2008011127A (es) INHIBIDOR DE 17ß HSD TIPO 5.
ATE393240T1 (de) Verfahren zum nachweis von prostatakrebs
DE60325834D1 (de) Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
ATE328874T1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
ATE450515T1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
GEP20074122B (en) Treating benign prostate hyperplasia with selective androgen receptor modulators
GB2399420A (en) Objective oriented NMR logging method and apparatus
TR199900556T2 (xx) Prostat hipertrofisini ve prostat kanserini tedavi etmek i�in vas�ta.
RU94046057A (ru) Ингибиторы активности тестостерон 5 альфа -редуктазы, фармкомпозиция, способ подавления активности, тестостерон 5 альфа -редуктазы
ATE129013T1 (de) Steroid 5-alpha-reduktase.
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
ATE177751T1 (de) Delta 16 ungesättigtes c17 heterocyclische steroide zur verwendung als steroid c17-20 lyase inhibitoren
TR200402566T2 (tr) Bitki transformasyon yöntemleri.
DE69703201D1 (de) Hydroxyamidinderivate verwendbar als stickoxidsynthese inhibitoren
DE69417925D1 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
MXPA04005417A (es) Uso de antagonista de h1 y un esteroide seguro para el tratamiento de la rinitis.
NO20031745D0 (no) Inhibisjon av vekstfaktoravhengigheten til tumorceller

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties